Provided by Tiger Trade Technology Pte. Ltd.

Cullinan Therapeutics

14.53
-0.8200-5.34%
Post-market: 14.690.1600+1.10%19:51 EDT
Volume:911.81K
Turnover:13.45M
Market Cap:935.07M
PE:-4.19
High:15.39
Open:15.22
Low:14.49
Close:15.35
52wk High:23.19
52wk Low:5.68
Shares:64.35M
Float Shares:48.08M
Volume Ratio:0.58
T/O Rate:1.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4680
EPS(LYR):-3.7236
ROE:-50.30%
ROA:-31.36%
PB:2.91
PE(LYR):-3.90

Loading ...

Cullinan Therapeutics initiates NDA for Zipalertinib

TIPRANKS
·
3 hours ago

New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line Egfr Exon 20 Insertion Mutation Nsclc for Review Under FDA Real-Time Oncology Review Program

THOMSON REUTERS
·
3 hours ago

Analysts Offer Insights on Healthcare Companies: AMN Healthcare Services (AMN) and Cullinan Management (CGEM)

TIPRANKS
·
Sep 25

Cullinan Therapeutics price target raised to $35 from $30 at H.C. Wainwright

TIPRANKS
·
Sep 25

Cullinan Therapeutics Price Target Maintained with a $40.00/Share by BTIG

Dow Jones
·
Sep 25

US Research Roundup-Chevron, Exxon Mobil, GoDaddy

Reuters
·
Sep 25

Matt Phipps Reiterates Buy on Cullinan Oncology, Citing Pullback-Driven Upside and Upcoming Q4 Clinical Data Catalysts

TIPRANKS
·
Sep 25

Cullinan Therapeutics share weakness provides buying opportunity, says TD Cowen

TIPRANKS
·
Sep 25

Cullinan falls after pushing rheumatoid arthritis data to December

TIPRANKS
·
Sep 24

Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio

GlobeNewswire
·
Sep 24

Small U.S. Stocks Close Lower; Cullinan Therapeutics Posts Biggest Loss

Dow Jones
·
Sep 24

Cullinan Therapeutics Down over 20%, on Track for Record Percent Decrease

Dow Jones
·
Sep 24

Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum

GlobeNewswire
·
Sep 22

Cullinan Management (CGEM) Gets a Buy from Wedbush

TIPRANKS
·
Sep 15

Analysts Have Conflicting Sentiments on These Healthcare Companies: Molina Healthcare (MOH), High Tide (HITI) and Cullinan Management (CGEM)

TIPRANKS
·
Sep 15

Cullinan Maintained at Buy on Zipalertinib Strength, Unchanged $33 Price Target

TIPRANKS
·
Sep 15

Cullinan Therapeutics Price Target Raised to $40.00/Share from $39.00 by BTIG

Dow Jones
·
Sep 15

Cullinan Therapeutics price target raised to $40 from $39 at BTIG

TIPRANKS
·
Sep 15

Cullinan Highlights Positive Phase 3 Lung Cancer Results

TIPRANKS
·
Sep 14

Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer

GlobeNewswire
·
Sep 14